復星醫藥AH股齊拉昇 研究顯示BNT162b2有效率高達93% 高於Moderna疫苗
格隆匯6月22日丨上午走勢偏弱的疫苗股午後在復星醫藥的拉昇帶動下集體走強,復星醫藥股一度拉昇漲超8%,H股一度拉昇漲超6%。6月3日在medRxiv平台上發佈的一項關於mRNA-1273(Moderna)和BNT162b2(輝瑞)的真實應用文章顯示,在完全接種mRNA疫苗後,Pfizer-BioNTech公司的BNT162b2有效率優於Moderna公司開發的mRNA-1273(93%>82%)。BNT162b2疫苗在接種第二劑以後,有效率大幅提升13個百分點。另外,研究還得出結論,注射mRNA疫苗不僅僅能夠降低人羣感染SARS-CoV-2的風險,一旦注射mRNA疫苗人羣感染SARS-CoV-2,患者的病情和疾病持續時間相比於未注射人羣都會大幅度降低。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.